InfoMoney PT

Patente do Ozempic já expirou – e a do Mounjaro, quando cai?

Projeto de lei na Câmara tenta antecipar quebra de exclusividade The post Patente do Ozempic já expirou – e a do Mounjaro, quando cai? appeared first on InfoMoney.

Mar 24, 2026 &03552424202631; 17:55 UTC www.infomoney.com.br

Read original on www.infomoney.com.br ↗

↘

Negative for markets

Sentiment score: -65/100

High impact Medium-term (weeks)

WHAT THIS MEANS

Ozempic's patent has expired and Brazilian legislation seeks to accelerate Mounjaro's patent expiration, enabling generic competition in the GLP-1 market. This threatens Novo Nordisk's pricing power and exclusivity in a high-growth therapeutic category.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

Novo Nordisk

NVOStock

Expected to decline

Novo Nordisk faces accelerated patent cliff on Mounjaro (tirzepatide) in Brazil; Ozempic already generic. Loss of exclusivity will compress margins and market share in a key emerging market.

↓

S&P 500

^GSPCIndex

Expected to decline

Pharma sector headwind; NVO is significant healthcare holding. Patent erosion in GLP-1 space signals regulatory pressure on high-margin biologics globally.

↓

Euro Stoxx 50

^STOXX50EIndex

Expected to decline

NVO is major STOXX 50 constituent; European pharma sentiment weakens on patent risk contagion.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

SHORT NVO on this fresh catalyst; patent cliff is material and Brazil legislation signals global regulatory trend. Avoid long pharma until clarity on Mounjaro timeline. Monitor for company guidance revision. [MOVE:2.1%]

KEY SIGNALS

Patent expiration catalyst (Ozempic already generic)Legislative acceleration of Mounjaro exclusivity breakMargin compression risk in high-growth GLP-1 categoryEmerging market regulatory pressure on pharma pricingVIX elevated (+4.7%) — risk-off environment favors defensive rotation away from growth pharma

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 24, 2026 at 18:00 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by InfoMoney. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Patente do Ozempic já expirou – e a do Mounjaro, quando cai?

RELATED INTELLIGENCE